A simple blood test during pregnancy which can detect Down's syndrome in the developing foetus is to be trialled by the NHS. The technique, known as Non-Invasive Prenatal Testing (NIPT), could significantly reduce the number of women needing invasive testing, which can cause miscarriage. The study, which is being carried out at Great Ormond Street Hospital, will assess how and when the blood test could be introduced across the NHS.
Currently a woman's risk is assessed using her age, an ultrasound scan, and markers in the blood. Those deemed at high risk of a child with Down's are then offered an invasive test. This involves using a needle to take a sample of either placental cells or of the fluid that bathes the baby - but this procedure carries a 1/100 chance of miscarriage. The aim of the new test is to reduce the number of women having the invasive test by more accurately assessing the risk.
The new blood test, which is already available privately, looks for tiny fragments of DNA from the placenta and the foetus floating in the mother's bloodstream. The test can analyse the free-floating DNA for extra copies of chromosome 21, which is the cause of Down's syndrome. It is thought to be 99% accurate, and those with a positive result will still have the option of undergoing the invasive procedure to confirm the result. Professor Lyn Chitty, from Great Ormond Street who is leading the trial, said; "It could very significantly reduce the number of invasive tests and increase detection, this is seriously exciting stuff and it would be great to get it into the NHS."
The NHS National Institute for Health Research funded trial will analyse the scale of the benefit, as well as the best way to inform mothers and train staff about the test. Professor Chitty explained that one of the very important aspects of the study is looking at ways to make sure women understand the test, so they will therefore know the implications of the results and be able to choose whether or not to have it. Dr Anna Mackie, from the UK National Screening Committee, said: "Early indications suggest that using NIPT to screen women who are found to be at a higher risk of having a baby with Down's syndrome would enable earlier and safer detection of the condition."
It is understood that the new test is approximately 99% accurate for women who have already been identified as being at high risk of having a baby with Down's syndrome. However, the researchers are interested to see whether that accuracy is maintained in women who have not been identified as high risk. The studies for this are still under way, but when they are completed the information obtained could then be provided to women and health professionals to improve understanding.
Jack
No comments:
Post a Comment